Skip to main content
. Author manuscript; available in PMC: 2022 Jun 8.
Published in final edited form as: Cancer Res. 2020 Nov 11;81(3):763–775. doi: 10.1158/0008-5472.CAN-20-2674

Figure 1. TFRC expression in DLBCL patients correlates with poor overall survival.

Figure 1.

A) Lenz et al. Kaplan-Meier overall survival (OS) analysis of high (red) vs. low (green) TFRC expression in 414 newly diagnosed untreated DLBCL patients. B) Reddy et al. Kaplan-Meier OS analysis of high (red) vs. low (green) TFRC gene expression from 756 DLBCL patients. Dotted lines indicate median OS. Lenz et al. median OS high = 4.99 years, low = 10.62 years (log-rank high/low HR 1.462, 95% CI 1.041 to 2.053). Reddy et. al median OS high = 7.840 years, low = 10.40 years (log-rank high/low HR 1.476, 95% CI 1.087 to 2.006).